Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): An Emphasis on preclinical and clinical catabolism

Current Drug Metabolism

Volumn 13, Issue 7, 2012, Pages 901-910

  Shen, Ben Quan ^a   Bumbaca, Daniela ^a   Saad, Ola ^a   Yue, Qin ^a   Pastuskovas, Cinthia V ^a   Khojasteh, S Cyrus ^a   Tibbitts, Jay ^a   Kaur, Surinder ^a   Wang, Bei ^a   Chu, Yu Waye ^a   LoRusso, Patricia M ^b   Girish, Sandhya ^a  

^a GENENTECH INC   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Absorption; Antibody drug conjugate; Catabolism; Distribution; Excretion; Metabolism; T DM1; Trastuzumab emtansine

Indexed keywords

DRUG METABOLITE; TRASTUZUMAB EMTANSINE;

ANIMAL EXPERIMENT; ARTICLE; BREAST METASTASIS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; FEMALE; HUMAN; NONHUMAN; RAT; SINGLE DRUG DOSE; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG EVALUATION, PRECLINICAL; FEMALE; MAYTANSINE; METABOLISM; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84865706368     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012802138598     Document Type: Article

References (19)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2011. http://www.nccn.org (Accessed July 13, 2011).
2. Carter, P.J.; Senter, P.D. Antibody-drug conjugates for cancer therapy. Cancer J., 2008, 14(3), 154-169.
3. Chari, R.V. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc. Chem. Res, 2008, 41(1), 98-107.
4. Erickson, H.K.; Park, P.U.; Widdison, W.C.; Kovtun, Y.V.; Garrett, L.M.; Hoffman, K.; Lutz, R.J.; Goldmacher, V.S.; Blättler, W.A. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intra-cellular processing. Cancer Res., 2006, 66(8), 4426-4433.
5. Erickson, H.K.; Widdison, W.C.; Mayo, M.F.; Whiteman, K.; Audette, C.; Wilhelm, S.D.; Singh, R. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug. Chem., 2010, 21(1), 84-92.
6. Chari, R.V.; Martell, B.A.; Gross, J.L.; Cook, S.B.; Shah, S.A.; Blättler, W.A.; McKenzie, S.J.; Goldmacher, V.S. Immunoconju-gates containing novel maytansinoids: promising anticancer drugs. Cancer Res., 1992, 52(1), 127-131.
7. Lewis Phillips, G.D.; Li, G.; Dugger, D.L.; Crocker, L.M.; Parsons, K.L.; Mai, E.; Blättler, W.A.; Lambert, J.M.; Chari, R.V.; Lutz, R.J.; Wong, W.L.; Jacobson, F.S.; Koeppen, H.; Schwall, R.H.; Kenkare-Mitra, S.R.; Spencer, S.D.; Sliwkowski, M.X. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res., 2008, 68(22), 9280-9290.
8. Junttila, T.T.; Li, G.; Parsons, K.; Phillips, G.L.; Sliwkowski, M.X. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensi-tive breast cancer. Breast Cancer Res. Treat., 2011, 128(2), 347-356.
9. Kovtun, Y.V.; Audette, C.A.; Mayo, M.F.; Jones, G.E.; Doherty, H.; Maloney, E.K.; Erickson. H.K.; Sun, X.; Wilhelm, S.; Ab, O.; Lai, K.C.; Widdison, W.C,; Kellogg, B.; Johnson, H.; Pinkas, J.; Lutz, R.J.; Singh, R.; Goldmacher, V.S.; Chari, R.V. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res., 2010, 70(6), 2528-2537.
10. Krop, I.E.; Beeram, M.; Modi, S.; Jones, S.F.; Holden, S.N.; Yu, W.; Girish, S.; Tibbitts, J.; Yi, J.H.; Sliwkowski, M.X.; Jacobson, F.; Lutzker, S.G.; Burris, H.A. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol., 2010, 28(16), 2698-2704.
11. Burris III, H.A.; Rugo, H.S.; Vukelja, S.J.; Vogel, C.L.; Borson, R.A.; Limentani, S.; Tan-Chiu, E.; Krop, I.E.; Michaelson, R.A.; Girish, S.; Amler, L.; Zheng, M.; Chu, Y.W.; Klencke, B.; O'Shaughnessy, J.A. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J. Clin. Oncol., 2011, 29(4), 398-405.
12. Krop, I.; LoRusso, P.; Miller, K.D.; Modi, S.; Yardley, D.; Rodri-guez, G.; Lu, M.; Burington, B., Agresta, S., Rugo, H. A phase 2 study of the HER2 antibody-drug conjugate trastuzumab-DM1 (T-DM1) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab, lapatinib, and chemo-therapy (abstract 277O). Ann. Oncol., 2010, 21(suppl 8), viii97.
13. Hurvitz, S.A.; Dirix, L.; Kocsis, J.; Gianni, L.; Lu, M.J.; Vinholes, J.; Song, C.; Tong, B.; Chu, Y.-W.; Perez, E.A. Trastuzumab em-tansine (T-DM1) versus trastuzumab + docetaxel in previously un-treated HER2-positive metastatic breast cancer (MBC): primary re-sults of a randomized, multicenter, open-label phase 2 study (TDM4450g). Eur. J. Cancer, 2011, 47(suppl 1), s330.
14. US National Institutes of Health. ClinicalTrials.gov: registry and results database Web site. http://www.clinicaltrials.gov/ct2/results? term=NCT00943670 (Accessed June 23, 2011)
15. Gupta, M.; Wang, B.; Carrothers, T.J.; Joshi, A.; LoRusso, P.M.; Chu, W.; Shih, T.; Loecke, D.; Girish, S. Exposure-response analy-sis in patients with HER2-positive (HER2+) metastatic breast can-cer (MBC) to assess the effect of T-DM1 QTc prolongation (ab-stract PII-64). Clin. Pharm. Ther., 2011, 89(suppl 1), S58.
16. Kuester, K.; Kloft, C. Pharmacokinetics of monoclonal antibodies. In: Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development, 6th ed.; Mei-bohm, B., Ed.; Wiley-VCH Verlag GmbH & Co. KGaA: Wein-heim, Germany, 2006, pp 45-92.
17. Sands, H.; Jones, P.L. Methods for the study of the metabolism of radiolabeled monoclonal antibodies by liver and tumor. J. Nucl. Med., 1987, 28(3), 390-398.
18. Guengerich, F.P. Cytochrome p450 and chemical toxicology. Chem. Res. Toxicol., 2008, 21(1), 70-83.
19. Girish, S.; Gupta, M.; Wang, B.; Lu, D.; Krop, I.E.; Vogel, C.L.; Burris, H.A. III.; LoRusso, P.M.; Yi, J.-H.; Saad, O.; Tong, B.; Chu, Y.W.; Holden, S.; Joshi, A. Clinical pharmacology of trastu-zumab emtansine (T-DM1): an antibody-drug conjugate in devel-opment for the treatment of HER2-positive cancer. Cancer. Che-mother. Pharmacol., 2012, [Epub ahead of print].